GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Price-to-Free-Cash-Flow

ACTU (Actuate Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 16, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Price-to-Free-Cash-Flow?

As of today (2025-05-16), Actuate Therapeutics's share price is $9.78. Actuate Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.57. Hence, Actuate Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Actuate Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

ACTU's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 29.53
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Actuate Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2024 was $-0.24. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.57.


Actuate Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Actuate Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Price-to-Free-Cash-Flow Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
- - -

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Actuate Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Actuate Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actuate Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's Price-to-Free-Cash-Flow falls into.


;
;

Actuate Therapeutics Price-to-Free-Cash-Flow Calculation

Actuate Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=9.78/-1.572
=N/A

Actuate Therapeutics's Share Price of today is $9.78.
Actuate Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.57.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Actuate Therapeutics  (NAS:ACTU) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Actuate Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Actuate Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.